Clinical Trial: Open-label, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07573111) titled 'Open-label, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation' on May 01.

Brief Summary: Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Acute Leukemia Myelodysplastic Syndrome

Intervention: BIOLOGICAL: QUAIL-100

live, attenuated bacterial therapeutic

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Laguna Biotherapeutics, Inc.

Publishe...